A cross-sectional study found that while the Inflation Reduction Act capped out-of-pocket drug costs for Medicare Part D beneficiaries at $2,000 starting in 2025, many enrollees may still face higher cost-sharing due to changes in plan design.
The research, published Aug. 18 in JAMA Health Forum, showed that between 2019 and 2025, both Medicare Advantage and Medicare Part D standalone plans saw rising deductibles and a greater reliance on coinsurance for name-brand drugs.
In Medicare Advantage Plans, the share of enrollees with coinsurance for brand-name drugs increased from 2.5% in 2024 to 27.7% in 2025. For standalone plans, the increase was gradual but persistent. The mean deductibles rose from $295 in 2019 to $490 in 2025, and the prevalence of beneficiaries with coinsurance for brand-name drugs increased from 21.9% to 84%.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
